Nocturnal Oxygenation Using a Pulsed-Dose Oxygen-Conserving Device Compared to Continuous Flow

Robert L Chatburn RRT-NPS FAARC, Joseph S Lewarski RRT FAARC, and Robert W McCoy RRT FAARC

BACKGROUND: The pulsed-dose oxygen-conserving device (PDOCD) has gained wide acceptance as a tool to reduce the cost and inconvenience of portable oxygen delivery. Despite the widespread use of PDOCDs in awake and ambulating patients, few studies report their use during sleep. This study was designed to compare heart rate and oxygen saturation (measured via pulse oximetry [SpO₂]) of sleeping patients using one brand of PDOCD versus continuous-flow oxygen. METHODS: We studied 10 home-oxygen patients who were using various continuous-flow oxygen systems and prescriptions. Baseline asleep and awake SpO₂ and heart rate were recorded while the patients used their existing home-oxygen systems (liquid oxygen or oxygen concentrator with nasal cannula) and continuous-flow oxygen prescription. Patients were then switched to a nasal cannula connected to a PDOCD. The PDOCD setting was adjusted to produce an SpO₂ equal to the patient’s awake baseline on continuous-flow. This setting was then used while the patient subsequently slept. Mean values for SpO₂ and heart rate and hours of sleep were calculated by the software in the oximeter. Mean values for SpO₂ and heart rate were compared with the paired Student’s t test. RESULTS: There was a statistically significant but clinically unimportant SpO₂ difference between the patients who used continuous-flow oxygen and those who used the PDOCD (95.7% vs 93.2%, respectively, p = 0.043). There was no difference in heart rate (77.3 beats/min vs 77.9 beats/min, p = 0.70). The sample size was adequate to detect a difference in heart rate of 5 beats/min at a power of 80%. For the subset of patients whose PDOCD triggering sensitivity was set on sensitive (vs the default lower sensitivity) there was a statistically significant but clinically unimportant SpO₂ difference (continuous-flow 95.6% vs PDOCD 93.2%, p = 0.044). All other comparisons showed no differences, but the sample sizes were too small to make any firm conclusions. One patient experienced an 11% SpO₂ drop with the PDOCD because of an inadequate triggering sensitivity setting. CONCLUSIONS: The PDOCD model we studied was able to deliver oxygen therapy (via nasal cannula) comparable to continuous-flow in 9 of 10 patients. The resting daytime SpO₂ on continuous-flow appears to be an appropriate target for setting the PDOCD to ensure adequate oxygenation, even

Robert L Chatburn RRT-NPS FAARC is affiliated with the Respiratory Care Department, University Hospitals of Cleveland, Cleveland, Ohio, and with the Department of Pediatrics, Case Western Reserve University, Cleveland, Ohio. At the time of this study, Robert L Chatburn RRT-NPS FAARC had no affiliation or financial relationship with Inogen Incorporated, Goleta, California. He is now a volunteer member of Inogen’s scientific advisory board; he receives no financial compensation from Inogen and has no financial relationship with Inogen.

Joseph S Lewarski RRT FAARC is affiliated with Inogen Incorporated, Goleta, California. At the time of this study, Joseph S Lewarski RRT was serving as a member of Inogen’s advisory board. He was not directly involved with patient study or data collection, but he received stock options in Inogen. In November 2004 he became an employee of Inogen.

Robert W McCoy RRT FAARC is affiliated with Valley Inspired Products, Apple Valley, Minnesota. At the time of this study, Robert McCoy RRT FAARC was an independent contractor consultant for Inogen. In January 2005 that consulting agreement ended, and since then he has had no financial relationship with Inogen.

This research was partly supported by Inogen Incorporated, Goleta, California, and by Valley Inspired Products, Minneapolis, Minnesota.

Robert L Chatburn RRT-NPS FAARC presented a version of this report at the 51st International Respiratory Congress of the American Association for Respiratory Care, held December 3–6, 2005, in San Antonio, Texas.

Correspondence: Robert L Chatburn RRT-NPS FAARC, Respiratory Care Department, University Hospitals of Cleveland, 11100 Euclid Avenue, Cleveland OH 44106. E-mail: robert.chatburn@uhhs.com.
During sleep, with the PDOCD we tested. We conclude that the PDOCD we tested is able to maintain adequate $S_{PO_2}$ during sleep in selected patients. Because of differences in design, triggering-signal sensitivity, and oxygen-pulse volume, these results cannot be generalized to all patients or all oxygen-conserving devices. Further research is needed to determine the general performance of PDOCDs on larger populations of oxygen-dependent patients and patients with sleep-disordered breathing. Key words: oxygen, pulsed-dose, conserving device, COPD, long-term oxygen therapy, oxygen inhalation therapy/methods. [Respir Care 2006;51(3):252–256. © 2006 Daedalus Enterprises]

Introduction

Pulsed-dose oxygen-conserving devices (PDOCDs) have become a clinical benchmark for nearly all compressed and liquid portable oxygen systems, and their use is considered a standard of practice with stable home-oxygen patients. Although PDOCD use is common in awake and ambulating patients, there is some hesitancy among many clinicians and providers regarding the use of PDOCDs at night. Despite published data suggesting that PDOCDs perform just as effectively during sleep,¹⁻³ there are some concerns regarding PDOCD triggering sensitivity and response to varying nocturnal breathing patterns. The objective of this study was to compare the heart rate and saturation of sleeping, oxygen-dependent patients using one PDOCD model, versus continuous-flow oxygen.

Methods

Patients with a primary diagnosis of emphysema or pulmonary fibrosis and with a history of prolonged oxygen use were recruited from the Minneapolis American Lung Association and volunteered to participate in the study. All the subjects were in the greater Minneapolis, Minnesota, area.

Patient Screening

Each patient either (1) had undergone a sleep-apnea study within the previous year or (2) underwent a nighttime sleep-apnea study, under the direction of Valley Inspired Products company (Apple Valley, Minnesota). The sleep-apnea studies were performed to rule out obstructive sleep apnea and to provide baseline blood oxygen saturation (measured via pulse oximetry [$S_{PO_2}$]) and heart-rate data, both awake and asleep. For the awake measurements, patients were monitored continuously for 20–30 min while seated and resting. The sleep studies were conducted in the patients’ homes, using their existing oxygen system (liquid oxygen or oxygen concentrator, with nasal cannula) and continuous-flow oxygen prescription. Valley Inspired Products provided an explanation of the study objectives and the study protocol to each patient and his or her physician, and obtained a signed patient consent form and a signed physician consent form for each patient included in the study. An apnea-hypopnea index (the total number of apneas and hypopneas per hour of sleep, calculated according to American Academy of Sleep Medicine standards) was recorded for each patient, by the software programmed into the sleep screening device (Third Shift, Valley Inspired Products, Apple Valley, Minnesota).

Study Design

Between 24 hours and 7 days after the initial sleep screening, patients entered the PDOCD study and acted as their own controls. None of the patients had any change in their clinical condition during the period between the sleep screening and the PDOCD study. Each patient was switched from their continuous-flow system to the PDOCD (Inogen One, Inogen, Goleta, California) with nasal cannula (model 1600, Salter Labs, Arvin, California) for one night. The PDOCD setting was adjusted to produce an $S_{PO_2}$ equal to the patient’s $S_{PO_2}$ on continuous-flow while awake, and this PDOCD setting was used while the patient slept.

The Inogen One PDOCD has 2 triggering sensitivity options: default, which triggers at 0.23 cm H₂O below atmospheric pressure, and sensitive, which triggers at 0.12 cm H₂O below atmospheric pressure. Seven patients were tested with the PDOCD on the sensitive setting, and 3 patients were randomly selected to be tested on the default setting. In this study the minimum acceptable sleep duration was 5 hours. Oximetry data were downloaded within 24 hours of the sleep period. Mean values for $S_{PO_2}$, heart rate, and hours of sleep were calculated by the software in the oximeter (Palmsat 2500 or WristOx 3100, Nonin Medical, Plymouth, Minnesota).

Statistical Analysis

Mean values for sleep hours, $S_{PO_2}$, and heart rate were compared with Student’s paired t test using statistical software (SigmaStat 3.0 for Windows, Aspire Software International, Leesburg, Virginia). Differences associated with p values ≤ 0.05 were considered significant. A power analysis was performed for nonsignificant results (using the Power and Precision software package, Biostat, Englewood, New Jersey). The power calculations were based on
the ability to detect a heart-rate difference of 5 beats/min and an $S_{\text{PO}_2}$ difference of 4%.

### Results

Ten patients were enrolled in the study (Table 1). Study data are displayed in Table 2. The mean continuous-flow setting was 2 L/min (range 0.75–3), and the mean PDOCD setting was 3 (range 1–5). PDOCD settings incorporate a combination of variables, including oxygen bolus size per setting, sensitivity, speed of response, bolus flow, and waveform. Therefore, it was not expected that the continuous-flow setting would consistently match the PDOCD setting, although this did occur in 20% of the patients.

The patients slept an average of 1 hour more when using the PDOCD than during the baseline sleep screening test ($p = 0.013$). There was a statistically significant but clinically unimportant difference in $S_{\text{PO}_2}$ between continuous-flow and PDOCD (95.7% vs 93.2%, $p = 0.043$). There was no difference in heart rate (77.3 beats/min vs 77.9 beats/min, $p = 0.70$). The sample size was adequate to detect a heart-rate difference of 5 beats/min at a power of 80%.

For the subset of patients whose PDOCD was set on sensitive, there was a statistically significant but clinically unimportant difference in $S_{\text{PO}_2}$ (continuous-flow 95.6% vs PDOCD 93.2%, $p = 0.044$). All other comparisons showed no differences, but the samples sizes were too small to make any firm conclusions (Table 3).

One patient in the default (lower) sensitivity group experienced a clinically important lower $S_{\text{PO}_2}$ with the PDOCD than with continuous-flow (86% vs 97%), and the oxygen concentrator data log suggested that he frequently failed to trigger the PDOCD throughout the sleep period.

### Discussion

PDOCDs minimize consumption of gas from portable oxygen sources. Advancements and improvements in PDOCD performance and reliability have stimulated the acceptance of many new oxygen technologies, including portable (<10 lbs) oxygen concentrators.

The PDOCD generally works by detecting the patient’s inspiratory effort and triggering the delivery of a small bolus of oxygen at the beginning of inspiration. The oxygen then remains off until the next inspiration is detected.

### Table 1. Patient Demographics

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age</th>
<th>Sex</th>
<th>Diagnosis</th>
<th>AHI</th>
<th>Years on Oxygen</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>73</td>
<td>M</td>
<td>Emphysema</td>
<td>1.0</td>
<td>3</td>
</tr>
<tr>
<td>2</td>
<td>65</td>
<td>F</td>
<td>Emphysema</td>
<td>2.6</td>
<td>6</td>
</tr>
<tr>
<td>3</td>
<td>58</td>
<td>M</td>
<td>Pulmonary fibrosis</td>
<td>0.8</td>
<td>3</td>
</tr>
<tr>
<td>4</td>
<td>73</td>
<td>M</td>
<td>Emphysema</td>
<td>9.0</td>
<td>3</td>
</tr>
<tr>
<td>5</td>
<td>77</td>
<td>M</td>
<td>Emphysema</td>
<td>4.4</td>
<td>0.4</td>
</tr>
<tr>
<td>6</td>
<td>71</td>
<td>F</td>
<td>Emphysema</td>
<td>5.0</td>
<td>6</td>
</tr>
<tr>
<td>7</td>
<td>74</td>
<td>F</td>
<td>Emphysema</td>
<td>5.0</td>
<td>2.5</td>
</tr>
<tr>
<td>8</td>
<td>76</td>
<td>F</td>
<td>Emphysema</td>
<td>3.8</td>
<td>7</td>
</tr>
<tr>
<td>9</td>
<td>72</td>
<td>F</td>
<td>Emphysema</td>
<td>NA</td>
<td>1.5</td>
</tr>
<tr>
<td>10</td>
<td>64</td>
<td>F</td>
<td>Emphysema</td>
<td>1.6</td>
<td>5</td>
</tr>
</tbody>
</table>

AHI = apnea-hypopnea index (total number of apneas and hypopneas per hour of sleep)
NA = data not available

### Table 2. Study Results

<table>
<thead>
<tr>
<th>Patient</th>
<th>Continuous-Flow (L/min)</th>
<th>PDOCD Sensitivity Setting</th>
<th>PDOCD Setting</th>
<th>Continuous-Flow</th>
<th>PDOCD</th>
<th>Hours of Sleep</th>
<th>Mean $S_{\text{PO}_2}$ (%)</th>
<th>Mean Heart Rate (beats/min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.75</td>
<td>Sensitive</td>
<td>1</td>
<td>7.4</td>
<td>9.2</td>
<td>94.0</td>
<td>93.2</td>
<td>−0.8</td>
</tr>
<tr>
<td>2</td>
<td>2</td>
<td>Sensitive</td>
<td>3</td>
<td>7.1</td>
<td>6.6</td>
<td>96.0</td>
<td>95.8</td>
<td>−0.2</td>
</tr>
<tr>
<td>3</td>
<td>2</td>
<td>Default</td>
<td>5</td>
<td>8.1</td>
<td>9.0</td>
<td>90.1</td>
<td>90.3</td>
<td>0.2</td>
</tr>
<tr>
<td>4</td>
<td>3</td>
<td>Sensitive</td>
<td>3</td>
<td>9.5</td>
<td>9.0</td>
<td>97.5</td>
<td>96.1</td>
<td>−1.4</td>
</tr>
<tr>
<td>5</td>
<td>2</td>
<td>Sensitive</td>
<td>2</td>
<td>7.2</td>
<td>8.6</td>
<td>96.9</td>
<td>94.6</td>
<td>−2.3</td>
</tr>
<tr>
<td>6</td>
<td>2</td>
<td>Sensitive</td>
<td>3</td>
<td>7.2</td>
<td>9.6</td>
<td>96.5</td>
<td>97.2</td>
<td>0.7</td>
</tr>
<tr>
<td>7</td>
<td>2</td>
<td>Sensitive</td>
<td>3</td>
<td>6.6</td>
<td>6.6</td>
<td>97.2</td>
<td>93.3</td>
<td>−3.9</td>
</tr>
<tr>
<td>8</td>
<td>2</td>
<td>Default</td>
<td>2.5</td>
<td>7.2</td>
<td>9.0</td>
<td>96.9</td>
<td>86.3</td>
<td>−10.6</td>
</tr>
<tr>
<td>9</td>
<td>2</td>
<td>Sensitive</td>
<td>3.5</td>
<td>5.1</td>
<td>7.2</td>
<td>96.5</td>
<td>94.0</td>
<td>−2.5</td>
</tr>
<tr>
<td>10</td>
<td>2.5</td>
<td>Default</td>
<td>3</td>
<td>5.6</td>
<td>6.5</td>
<td>95.0</td>
<td>91.6</td>
<td>−3.4</td>
</tr>
</tbody>
</table>

| Mean    | 7.1                     | 8.1                       | 95.7           | 93.2            | 2.4            | 10.4                        | 10.3                        | 5.0                         |

PDOCD = pulsed-dose oxygen-conserving device
SD = Standard deviation
At a 2-L/min setting on a typical PDOCD, the bolus is generally between 15 mL and 36 mL. A variation on this design is to deliver the bolus on selected breaths, depending on the oxygen prescription (eg, a pulsed dose on every fourth breath would equate to 1 L/min of continuous flow).5

Like other PDOCDs, the Inogen One uses pressure sensing to identify the onset of inspiration and trigger delivery of a bolus of oxygen in the first 100 ms of the breath. Unlike other PDOCDs, the Inogen One has a microprocessor that monitors the respiratory rate and adjusts the bolus volume to maintain a consistent minute volume of oxygen. For example, at the setting, the device delivers a fixed volume of 300 mL of oxygen per minute. At 10 breaths/min, each bolus is 30 mL. At 20 breaths/min each bolus is 15 mL. If a patient takes a long pause (ie, apnea), the next bolus is adjusted up. This oxygen dosing method might partially explain the results of the present study. A common concern regarding PDOCD use during sleep is the effect of slower respiratory rate and smaller tidal volume (hypoventilation) on oxygenation. In response to a decreasing respiratory rate, the Inogen One increases the bolus size per breath, which increases the fraction of inspired oxygen (FIO2) per breath. If the tidal volume decreases, the effect of increasing FIO2 would be even greater. This effect on breath-by-breath FIO2 might tend to offset any decrease in oxygen delivery due to breaths that failed to trigger the PDOCD. We speculate that this approach to oxygen delivery, in conjunction with effective trigger sensitivity, may prove more effective than the conventional PDOCD design in maintaining adequate and consistent S\textsubscript{PO2} during sleep.

As a consequence of PDOCDs being pressure-triggered, there is a legitimate concern on the part of caregivers that PDOCDs might fail with patients who have sleep-disordered breathing. For this reason we restricted our study to patients who had no substantial sleep apnea. All the patients in our study had an apnea-hypopnea index below 10. This is a limitation of the study, and the results cannot be generalized to all patients who require nocturnal oxygen. The apnea-hypopnea index has become the standard by which to define and quantify the severity of obstructive sleep apnea-hypopnea syndrome. An apnea-hypopnea index greater than 15 events per hour indicates possible presence of the syndrome. Generally, as the apnea-hypopnea index increases, the severity of apnea increases.6

Bower et al2 compared continuous-flow to demand pulse-dosed oxygen during all patient activities, including sleep. They concluded that demand oxygen systems produced arterial oxygenation equivalent to continuous-flow during all activities.

In a large (n = 100), unblinded, cross-over study that compared continuous-flow oxygen to pulse-dosed oxygen in hospitalized patients, Kerby et al1 concluded that the PDOCD and continuous-flow systems they tested produce similar S\textsubscript{PO2} in hypoxemic patients over the course of day and night.

More recently, Cuvelier et al,3 using polysomnography, compared the efficacy of continuous-flow and pulse-dosed oxygen in sleeping, hypoxemic patients. The PDOCD (as compared to continuous-flow) did not induce any significant alteration in physiologic variables in the majority of patients with moderate-to-severe chronic obstructive pulmonary disease who required supplemental oxygen.

The results of the present study agree with these previous studies. The Inogen One provided the same clinical benefit as a continuous-flow nasal cannula in 90% of a small sample of patients. Regarding the one study subject in the default (lower) triggering sensitivity group who experienced a clinically important lower S\textsubscript{PO2} with the PDOCD (86% vs 97%), it is important to note than no device adjustments, titrations, or retesting were performed during the single-night study. In actual clinical practice this could

### Table 3. Results of Statistical Tests

<table>
<thead>
<tr>
<th>Test</th>
<th>Condition</th>
<th>Continuous-Flow (%)</th>
<th>PDOCD (%)</th>
<th>p</th>
<th>Power (%)</th>
<th>Continuous-Flow (%)</th>
<th>PDOCD (%)</th>
<th>p</th>
<th>Power (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>All patients</td>
<td>95.7</td>
<td>93.2</td>
<td>0.043</td>
<td>N/A</td>
<td>77.3</td>
<td>77.9</td>
<td>0.703</td>
<td>80</td>
</tr>
<tr>
<td>2</td>
<td>Set on sensitive</td>
<td>96.4</td>
<td>94.9</td>
<td>0.044</td>
<td>N/A</td>
<td>74.6</td>
<td>73.8</td>
<td>0.652</td>
<td>68</td>
</tr>
<tr>
<td>3</td>
<td>Set on default</td>
<td>94.7</td>
<td>89.4</td>
<td>0.284</td>
<td>12</td>
<td>83.7</td>
<td>87.7</td>
<td>0.287</td>
<td>18</td>
</tr>
</tbody>
</table>

**Effect Size for Power Analysis**

\[
\text{effect size} = \frac{\text{desired detectable difference}}{\text{standard deviation of differences}}
\]

- **All patients:**
  - effect size (heart rate) = 5/4.99 = 1.0
  - effect size (SpO2) = 4/5.50 = 0.7

- **Set on sensitive:**
  - effect size (heart rate) = 5/4.63 = 1.1
  - effect size (SpO2) = 4/5.41 = 1.0

PDOCD = pulsed-dose oxygen-conserving device
be remedied by increasing the sensitivity and the oxygen setting during sleep.

We used the awake baseline $S_{PO_2}$ as the target for setting the during-sleep oxygen delivery. One might expect the asleep oxygen requirement to be more than the awake requirement to maintain the same $S_{PO_2}$, yet our results showed equivalent $S_{PO_2}$. Also, 7 of the 10 patients slept longer with the PDOCD than during the initial sleep screening. These findings lead us to be even more confident in our conclusions.

**Conclusions**

With the Inogen One PDOCD, 9 of 10 patients maintained nocturnal $S_{PO_2}$ and heart rate that were clinically equivalent to their continuous-flow baseline values. One patient failed to trigger the PDOCD appropriately and therefore experienced an 11% lower $S_{PO_2}$ with the PDOCD, whereas all the other patients maintained $S_{PO_2}$ within 4% of their continuous-flow baseline while using the PDOCD. None of the patients had a history of substantial apnea-hypopnea. The resting daytime $S_{PO_2}$ on continuous-flow appears to be an appropriate target for setting the PDOCD to ensure adequate oxygenation, even during sleep, with the Inogen One. With the Inogen One we recommend the sensitive setting during sleep.

We conclude that the Inogen One is able to maintain adequate $S_{PO_2}$ during sleep in selected patients. Because of differences in design, triggering-signal sensitivity, and pulse volume, these results cannot be generalized to all patients or all PDOCDs. Further research is needed to determine the general performance of PDOCDs in larger populations of oxygen-dependent patients and patients with sleep-disordered breathing.

**REFERENCES**

DETERMINATION OF AN APPROPRIATE NOCTURNAL SETTING FOR A PORTABLE OXYGEN CONCENTRATOR WITH PULSE-DOSED DELIVERY

J Stegmaier, RRT-NPS, RPFT, CCM1, R Chatburn, BS, RRT-NPS, FAARC2, J Lewarski, BS, RRT, FAARC3
1Cardinal Home Respiratory, Cleveland, OH, 2Chatburn Consulting, Cleveland, OH, 3Inogen, Inc., Goleta, CA

Introduction: Expert recommendations suggest titration of long-term oxygen therapy (LTOT) settings to the patient’s activity level. However, clinicians in the US routinely specify a continuous flow (CF) oxygen prescription (i.e., 2 L/min) and employ this prescription during all activities of daily living (ADL), including sleep. New portable oxygen concentrators (POC) that operate using an integrated and real-time pulse-dosed oxygen delivery (PDOD) device are now readily available. There are published data supporting the safe and effective use of appropriately titrated oxygen using a PDOD at all activity levels, including sleep. The purpose of this study was to determine if a single titration of oxygen using a POC during exercise would provide an appropriate setting for nocturnal use.

Methods: We selected the Inogen One™ POC (Inogen, Inc., Goleta, CA) because: (1) it is FDA 510(k) cleared for use as described, (2) it is the only POC currently recognized by Medicare as both a stationary and portable O2 device and (3) it incorporates modern PDOD technology specifically designed for use at night. Eleven (11) oxygen patients were randomly selected from a mix of newly referred and existing home LTOT patients. Additional selection criteria included a CF prescription of ≤ 4 L/min, a diagnosis of COPD, age range 55-80 years and no known evidence of obstructive sleep apnea. All patients signed an informed consent prior to enrollment in the study and all had valid prescriptions for O2, PDOD and clinical assessment/oximetry. Patients were titrated by a respiratory therapist to a POC setting that produced a SpO2 of > 90% during a 3-minute walk/ADL challenge. For sleep, patients were instructed to select the “sensitive” PDOD setting and the highest oxygen setting used during the walk/ADL assessment. All patients underwent a single overnight pulse oximetry study while using the POC. Clinically significant nocturnal oxygen desaturation (NOD) was defined as ≥ 20 cumulative minutes below a SpO2 of 88% or ≥ 5% of their total sleep time below 88%. Patients were returned to their original oxygen device upon completion of the study.

Results: No patients experience clinically significant oxygen desaturation during sleep. Mean (standard deviation) clinical evaluation results are reported:

<table>
<thead>
<tr>
<th>POC Setting</th>
<th>Nocturnal SpO2</th>
<th>Cumulative minutes NOD</th>
<th>% Sleep time NOD</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.6 (0.5)</td>
<td>92% (1%)</td>
<td>3.3 (2.6)</td>
<td>1.3% (0.8%)</td>
</tr>
</tbody>
</table>

Conclusion: Nocturnal POC oxygen setting selection based on daytime ADL/ambulation appears to produce effective nocturnal oxygen therapy as evidenced by a mean sleeping SpO2 of 92% and no clinically significant NOD. These results suggest that a single, one-step clinical evaluation and titration of oxygen setting with one brand of POC/PDOD device can produce effective oxygenation at rest, with ADL/ambulation and during sleep. Because of differences in design, signal sensitivity, and pulse volume, these results cannot be generalized to all POC and PDOD devices.

Original Publication
Respiratory Care
November 2006;51(11): 1305
Chronic Obstructive Pulmonary Disease and Sleep

Peter C Gay MD

Introduction
How Are Normal Control of Breathing During Sleep and Sleep Quality Altered in COPD Patients?
How Should We Evaluate COPD Patients for Sleep-Related Breathing Disorders?
How Are Co-Existing COPD and Sleep-Related Breathing Disorders Best Managed?
How Is the Management of Sleep-Related Breathing Disorders in COPD Patients Complicated by Process and Reimbursement Issues?

Oxygen
Noninvasive Positive-Pressure Ventilation

The control of breathing in patients with chronic obstructive pulmonary disease (COPD) follows the same basic principles as in normal subjects, both awake and asleep, with an expected lower feedback response during sleep. This impacts nocturnal gas exchange and sleep quality most profoundly in patients with more severe COPD, as multiple factors come into play. Hypoventilation causes the most important gas-exchange alteration in COPD patients, leading to hypercapnia and hypoxemia, especially during rapid-eye-movement sleep, when marked respiratory muscle atonia occurs. The hypoxia leads to increased arousals, sleep disruption, pulmonary hypertension, and higher mortality. The primary mechanisms for this include decreased ventilatory responsiveness to hypercapnia, reduced respiratory muscle output, and marked increases in upper airway resistance. In the presence of more profound daytime hypercapnia, polysomnography should be considered (over nocturnal pulse oximetry) to rule out other co-existing sleep-related breathing disorders such as obstructive sleep apnea (overlap syndrome) and obesity hypoventilation syndrome. Present consensus guidelines provide insight into the proper use of oxygen, continuous positive airway pressure, and nocturnal noninvasive positive-pressure ventilation for those conditions, but several issues remain contentious. In order to provide optimal therapy to patients, the clinician must take into account certain reimbursement and implementation-process obstacles and the guidelines for treatment and coverage criteria. Key words: chronic obstructive pulmonary disease, COPD, obstructive sleep apnea, continuous positive airway pressure, CPAP, oxygen, hypertension, obesity, hypoventilation, noninvasive positive-pressure ventilation, NPPV. [Respir Care 2004;49(1):39–51. © 2004 Daedalus Enterprises]
**Introduction**

This discussion will begin with commentary about the ventilatory changes that normally occur in humans during sleep and will then review the gas exchange abnormalities and typical sleep characteristics of chronic obstructive pulmonary disease (COPD) patients. I will then comment on ways to evaluate COPD patients for sleep-related breathing disorders and the approach to management as it affects COPD patients during sleep. Reimbursement and implementation process issues that influence treatment decision-making will be addressed and, finally, I will discuss summary indications and recommendations for nocturnal oxygen therapy (NOT) and noninvasive positive-pressure ventilation (NPPV) to provide optimal therapy for COPD patients. Identification of gas exchange and sleep issues as well as management of sleep disorders in COPD patients will be addressed through responses to the following questions:

- How are normal control of breathing during sleep and sleep quality altered in COPD patients?
- How should we evaluate COPD patients for sleep-related breathing disorders?
- How are co-existing COPD and sleep-related breathing disorders best managed?
- How is the management of sleep-related breathing disorders in COPD complicated by process and reimbursement issues?
- What are the summary indications for supplemental oxygen and NPPV during sleep in COPD patients?

---

Peter C Gay MD is affiliated with the Department of Pulmonary, Critical Care, and Sleep Medicine, Mayo Clinic and Foundation, Rochester, Minnesota.

Peter C Gay MD presented a version of this report at the 32nd Respiratory Care Journal Conference, Chronic Obstructive Pulmonary Disease: Translating New Understanding Into Improved Patient Care, held July 11–13, 2003, in Los Cabos, Mexico.

Disclosures: Studies of patients with obstructive sleep apnea are ongoing with grants from Respironics Inc. Peter C Gay MD receives no consulting fees from nor does he have any financial investments in Respironics Inc or other corporations with a financial interest in products or therapies discussed in this article.

Correspondence: Peter C Gay MD, Mayo Clinic and Foundation, 200 First Street SW, Rochester MN 55905-0001. E-mail: pgay@mayo.edu.

---

**How Are Normal Control of Breathing During Sleep and Sleep Quality Altered in COPD Patients?**

Normal control of breathing and sleep physiology in adults have been reviewed elsewhere but a brief overview of assessment techniques and findings provides a useful foundation for discussion. Breathing during sleep is typically characterized by measurement of gas exchange via pulse oximetry and ventilatory effort or assessment of respiratory muscle output and airflow (pneumotachography, spirometry, or electromyography), or pressure generated by respiratory muscles. Sleep quality is measured with electroencephalography, which identifies specific sleep stages, which are organized primarily as they relate to rapid-eye-movement (REM) sleep and non-REM sleep. Guidelines are available that provide consensus on the standardization for study. Variables such as sleep efficiency, which is the total sleep time divided by total time of electroencephalographic recording, and sleep disruptions (arousals) can be tabulated and are useful descriptors.

The normal sleep pattern follows a periodic pattern, cycling every 90–120 min, that sequences through variable stages of non-REM sleep and culminates in an episode of REM sleep. Breathing responses are distinctly different during REM and non-REM sleep. REM sleep is subdivided into 2 periods: tonic and phasic. The entire REM period is uniquely characterized by absence of electroencephagram-detectable skeletal muscle tone, but the phasic period is further identified by bursts of unsynchronized rapid eye movements. Respiration becomes more irregular and autonomic tone increases during REM sleep, while thermoregulatory control changes (mammals assume a poikilothermic state). A basic dictum is that the physiologic mechanisms that control breathing during the awake state are operative during sleep except that the response magnitudes are altered; the magnitude of response and feedback networks is usually reduced. Figure 1 shows the factors that influence control of breathing during sleep.

Gas exchange is altered, with minor but significant reduction in $P_{aO_2}$ and increase in $P_{aCO_2}$, most obviously during REM sleep. The normal ventilatory response to hypercapnia and hypoxia are blunted, compared to during the awake state, most obviously during REM sleep (Figs. 2 and 3). The ventilatory and arousal responses to hypercapnia are much more robust than for hypoxia, with only slight changes in $P_{aCO_2}$ causing recognizable alterations of minute ventilation ($V_{\text{E}}$). Diaphragm contractility is reduced with hypercapnia and can lead to muscle fatigue and further reduction in ventilatory responsiveness. Arousal responses are much more variable with hypoxia, and many subjects do not arouse even when oxygen saturation is forced to go as low as 70%. The reaction to hypoxic challenge is also distinctly affected by gender, with female subjects being more responsive.
Major changes in upper airway resistance and tidal volume ($V_T$) also occur during sleep. Animal studies reveal that local lung receptor nerve traffic influences breathing pattern, which varies with sleep stage and vagal activity. Despite a slight increase in respiratory rate, $V_{\dot{E}}$ in animals and normal subjects decreases, especially during REM sleep, due primarily to reduced $V_T$. The lung volume and gas exchange alterations are more pronounced in COPD patients; they show modest decreases in functional residual capacity during all sleep stages and this may cause substantial ventilation-perfusion ($V/Q$) mismatch, leading to hypoxemia. One study showed that COPD patients have similar degrees of hypoventilation regardless of whether they are major or minor sleep desaturators, which suggests that $V/Q$ mismatch plays an important role in nocturnal gas-exchange derangement.

The researchers proposed that $V/Q$ mismatch must be influential, but the study was criticized for using end-tidal carbon dioxide measurement to assess the degree of hypoventilation; that technique may not accurately reflect $P_{aCO_2}$ in these patients. The possible mechanisms for reduced functional residual capacity include respiratory muscle hypotonia, cephalad displacement of the diaphragm with recumbency, and decrease in lung adherence. Because of the REM-related atonia of the intercostal and other accessory muscles, the relative contribution of the various respiratory muscles also changes dramatically.

The change in $V_{\dot{E}}$ during sleep is difficult to study accurately and most often has been described using inductance plethysmography, but recent studies with COPD patients used more elegant techniques. When $V_{\dot{E}}$ was measured with a pneumotachograph and arterial oxygen saturation was measured via pulse oximetry ($S_{pO_2}$), patients with severe COPD had nearly 20% lower oxygenation during non-REM sleep and 40% lower oxygenation during REM sleep than during the awake state, primarily due to reduced $V_T$. An "iron lung" converted to act as a body plethysmograph was used to study 5 patients with severe COPD during sleep, and those cases indicated that neither lung volume nor lower-airway resistance changed.

The researchers thought that $V/Q$ mismatching does not play a major role in nocturnal gas-exchange derangement. They confirmed a $V_{\dot{E}}$ decrease, by as much as 35%, during REM sleep, due to decreased $V_T$. Their most impressive findings were related to the marked increase in upper airway resistance: 163% in non-REM sleep and 264% in REM sleep. In addition there was a marked decrease in
respiratory neuromuscular output during sleep, as measured via esophageal occlusion pressure, which fell 39% during REM sleep. They concluded that sleep does not seem to alter lung volume or increase lower-airway resistance dramatically, but a decrease in \( V_T \) and inspiratory flow are associated with increased upper airway resistance and reduced respiratory muscle activity. There is, however, a normal circadian rhythm to airway constriction, increasing slightly in normal subjects but much more in patients who have asthma as a component of their COPD. 26,27

With respect to sleep quality, COPD patients are more likely to regularly use hypnotic medications and have more difficulty falling and staying asleep, and they have more daytime sleepiness. The sleep fragmentation is related to the level of nocturnal desaturation, especially during REM sleep, and the increased number of arousals correlates strongly with this. 20,28,29

COPD patients with more severe obstruction and hypoxemia have much less total sleep time and time in REM sleep during a given sleep period, with 3 times more frequent sleep-stage changes. 20 The shorter total sleep time and numerous arousals seen in patients with milder awake hypoxemia and airway obstruction do not seem to result in objective or subjective evidence of daytime sleepiness.

Unfortunately, in the study noted above there was no improvement in the reduced sleep time and increased sleep stage changes, even when nocturnal desaturation was effectively treated, despite patients also reporting subjective improvement in sleep quality with oxygen (Fig. 4). In a smaller study, nocturnal oxygen significantly increased sleep time as well as the number and duration of REM periods in hypoxemic and hypercapnic COPD patients. 28

Other common coexisting medical problems, such as gas-

troesophageal reflux, could contribute to sleep disruption and should not be overlooked. 30

**How Should We Evaluate COPD Patients for Sleep-Related Breathing Disorders?**

Nocturnal oxygen desaturation (NOD) has long been recognized in COPD patients, 21,24,31–33 who may spend > 30% of sleep time with oxygen saturation < 90% or > 5% of sleep time below awake \( S_{O_2} \), mostly during REM sleep (Figure 5). The degree of nocturnal desaturation differs markedly among COPD patients and is often difficult to predict. Pulmonary function testing correlates poorly with nocturnal hypoxemia. 19 Nocturnal hypoxemia is affected by co-morbidities such as heart failure and obstructive sleep apnea (OSA), which were not always excluded in studies. 29 Patients with more chronic bronchi-
tis (“blue bloaters”) show the best correlation between awake oxygen saturation and lowest saturation, when cardiac arrhythmia are also likely to occur. 28,29,34 The maximum change in nocturnal oxygen saturation has been negatively correlated with the awake ventilatory response to hypercapnia and awake oxygen saturation. 33 The hypoxic ventilatory response during the awake state is not useful in predicting nocturnal oxygen saturation change, but moderate desaturation during exercise does have some predictive value for reduced nocturnal mean and nadir saturation. 19,31

There is no universal agreement as to how and when COPD patients should be evaluated for nocturnal hypoxemia, because it is controversial what level of nocturnal hypoxemia merits treatment, who should be treated, and how aggressively to follow it. Both the Report of the Medical Research Council Working Party and the Nocturnal Oxygen Therapy Trial demonstrated improved survival with the continuous use of long-term oxygen therapy (LTOT) when including the hours of sleep. 35,36 In the Nocturnal Oxygen Therapy Trial, the survival advantage also paralleled a reduced rate of progression for pulmonary hypertension. 37 A joint effort by the American Thoracic Society and the European Respiratory Society is underway to revise the standards for evaluation and treatment of COPD patients. The standards will include those patients with NOD who do not meet current recommended criteria for treatment with continuous oxygen therapy. It is not expected that there will be major changes for this category, compared to the 1995 guidelines. 38

- Nocturnal oxygen should be prescribed to patients who suffer substantial desaturation (≤ 88%) during sleep. This can generally be predicted from daytime hypoxia (\( P_{O_2} < 55 \text{ mm Hg} \)), and the goal is to maintain arterial oxygen saturation (\( S_{O_2} \)) > 90% for 70% of the time.

- Measuring nocturnal oxygen saturation in COPD pa-

tients who have daytime \( P_{O_2} \) of 55–59 mm Hg is not
recommended, except in patients with unexplained polycythemia or cor pulmonale, in which case oxygen flow should be titrated to maintain $P_aO_2 > 60$ mm Hg. Full polysomnography should be performed with COPD patients whose symptoms suggest coexistent OSA.

There is evidence to support a more aggressive stance with NOD than the ATS guidelines suggest. In a large registry of patients who died with severe COPD after being treated with LTOT, death during sleep occurred in 20% and unexpectedly in 26% of those deaths.\(^3\) One large study examined the relationship between NOD and mortality in 169 COPD patients with daytime $P_aO_2 > 60$ mm Hg, using 2 definitions.\(^4\) Definition 1 included patients with $S_pO_2 < 90\%$ for 5 min to a nadir of at least 85%, to focus on episodic desaturation associated mainly with REM sleep. Definition 2 enrolled patients who had $> 30\%$ of the time-in-bed with $S_pO_2$ below 90%. Patients with NOD spent a mean ± SD 134 ± 111 min below 90% $S_pO_2$, such that around 20 min reduction below that level included 90% of patients. The non-NOD subjects’ survival (corrected for age) was significantly better, but when NOD subjects were stratified for supplemental oxygen use, survival remained better only in subjects separated by definition 1, with a nonsignificant trend toward better survival among the 35 oxygen-treated subjects, compared to the 38 non-oxygen-treated subjects.

The development of increased pulmonary vascular resistance and poorer survival has been correlated with more pronounced NOD, especially during REM sleep.\(^5\) Pulmonary artery pressure is less pronounced in patients who have NOD than in those who do not, and oxygen has a protective effect on supporting better nocturnal pulmonary hemodynamics.\(^6\) Mean pulmonary artery pressure actually fell in NOD patients who received (for 36 months) oxygen during sleep, compared to patients given sham treatment (defective oxygen concentrator).\(^7\) Another study assessed whether COPD patients with NOD by definition 2 above develop increased pulmonary artery pressure.\(^8\) NOD occurred in 82% of patients and was predicted by both forced expiratory volume in the first second ($FEV_1$) and $P_aCO_2$ level. Mean nocturnal $S_pO_2$, correlated with body

---

Fig. 5. Overnight recordings of: (top curve) electroencephalographically-measured sleep stage (in which the shaded areas represent rapid-eye-movement sleep); (middle curve) ear-measured oxygen saturation; (bottom curve) transcutaneously-measured $P_aO_2$; and (circled values) intermittently measured $P_vO_2$ in a 55-year-old male patient with chronic obstructive pulmonary disease. (From Reference 33, with permission.)
mass index and P_{aCO_2}, but not with P_{aO_2}. On the other hand, not even multi-variate analyses were capable of predicting the presence of pulmonary hypertension.

In a randomized trial, 135 consecutive stable COPD patients with definition 2 NOD were evaluated after an average of 40 months of oxygen use (12–14 h/d); oxygen failed to show survival benefit, despite nearly 30% mortality in the first 3 years.\(46\)

A 2-year, randomized trial in European study 66 COPD patients who had mean daytime P_{aO_2} of 56–69 mm Hg and NOD but no OSA (measured via polysomnography). Forty-one patients received NOT with a goal of S_{pO_2} > 90% all night, and 35 patients received no NOT.\(47\) The measured variables included pulmonary hemodynamic effects, survival, and requirement for LTOT. The 2 groups were well matched, with identical baseline mean ± SD daytime P_{aO_2} \((63 ± 3\) mm Hg). Twenty-two patients \(12\) in the NOT group and 10 in the control group) required LTOT all night, and 35 patients received no NOT.\(47\) The average of 40 months of oxygen use \((12\) patients with definition 2 NOD were evaluated after an average of 40 months of oxygen use \(12\) h/d); oxygen did not affect survival. Nevertheless, the researchers concluded that use of NOT for this group of COPD patients is probably not justified.

With the ready availability and low cost of nocturnal oxygen saturation studies, it seems prudent to also be more attentive to saturation measurement in patients who have moderate COPD and possible NOD. As noted above, there is guarded consensus on the use of alternative predictors of NOD. Awake S_{pO_2} and lowest exercise S_{pO_2} during a 6-min walk test are the standard methods of determining a patient’s need for LTOT, but those measures correlated poorly with oxygenation measures during sleep or activities of daily living in a prospective, cohort study of 20 stable COPD patients.\(48\)

The ATS guidelines encourage increasing oxygen flow by 1 L/min during sleep in COPD patients receiving LTOT, but a study of 82 consecutive severe-COPD patients \(mean ± SD\) FEV_1 \(0.87 ± 0.33\) L, P_{aO_2} \(51.6 ± 5\) mm Hg, and P_{aCO_2} \(47 ± 8\) mm Hg) suggested otherwise.\(38\) Thirty-nine patients \(47.6\%\) spent \(> 30\%\) of the night with S_{pO_2} < 90\% while breathing supplemental oxygen. Their mean ± SD overnight S_{pO_2} while breathing oxygen was 87.1 ± 4.5\%, and the percentage of the recording time spent with S_{pO_2} < 90\% was 66.1 ± 24.7\%. Comparison of ventilatory variables and daytime blood gases between both groups revealed statistically significantly higher P_{aCO_2} on air \(p < 0.001\) or on oxygen \(p < 0.05\) and lower P_{aO_2} on oxygen \(p < 0.05\) in the group of patients demonstrating this substantial nocturnal desaturation. The researchers concluded that about half of COPD patients receiving LTOT need oxygen flow increases \(> 1\) L/min during sleep, especially those with both P_{aCO_2} ≥ 45 mm Hg and P_{aO_2} < 65 mm Hg while breathing oxygen.

Polysomnography is generally not recommended for COPD patients except in a subset population.\(50\) The term “overlap syndrome” was introduced by David Flennley to describe OSA in association with COPD, in which gas exchange and symptoms seemed out of proportion to the degree of airway obstruction.\(51\) Clinicians were cautioned to suspect COPD patients who are hypercapnic but have only moderately severe reduction in FEV_1, who are obese snorers, or who get headache after NOT. Daytime hypercapnia in COPD patients, then, may also be associated with OSA or other types of sleep-related breathing disorders, such as obesity hypoventilation syndrome, and require further evaluation and treatment.\(52\)

The prevalence of hypercapnia was investigated in a review of 219 consecutive patients evaluated in a sleep center.\(53\) Overall, only 17\% had hypercapnia \(P_{aCO_2} > 45\) mm Hg), with 3 distinct groups having some distinguishing features. As expected, the overlap patients \(10\%) had more airway obstruction, and the degree of hypercapnia was correlated with the obstruction. The obesity hypoventilation syndrome patients \(13\%) were younger, heavier, and the most hypercapnic, with P_{aCO_2} related to the degree of restrictive lung disease. The remaining patients \(77\%) had more “pure” OSA, but the apnea-hypopnea index did not help distinguish the degree of hypercapnia. Awake hypercapnia worsens during sleep in patients with chronic bronchitis, obesity hypoventilation syndrome, and overlap syndrome, such that these patients are more prone to develop cor pulmonale or congestive heart failure and have a poorer prognosis.\(54\) When P_{aCO_2} increases in a COPD patient during the first 6–18 months of LTOT, this also portends a higher mortality rate.\(56\) The arterial blood gas values may serve as a useful warning sign for patients prone to exaggerated daytime, and especially nocturnal, hypoxemia with LTOT.

Patients with milder COPD were recently the subject of a large study done in conjunction with the Sleep Heart Health Study group.\(57\) The Sleep Heart Health Study enrolled 5,954 patients who underwent unattended home polysomnography and spirometry, with a total of 1,132 participants who had predominantly mild COPD \(mean ± SD\) ratio of FEV_1 to forced vital capacity \(FVC\) \(63.81 ± 6.56\%). The prevalence of sleep apnea-hypopnea was not greater when using a respiratory disturbance index threshold of \(> 10\) events per hour with, versus without, mild COPD \(22.3\% vs 28.9\%, respectively). Participants with both COPD and sleep apnea-hypopnea had greater sleep disruption and desaturation than those with either disorder alone, but generally mild COPD alone was associated with
minimally altered sleep quality. In the absence of sleep apnea-hypopnea but with FEV₁/FVC < 65%, the adjusted odds ratio for sleep desaturation (≥ 5% total sleep time with S₉₀₂ < 90%) was > 1.9. The researchers concluded that there is no relationship between generally mild COPD and sleep apnea-hypopnea, but an FEV₁/FVC < 65% is associated with higher risk of sleep desaturation and is greater with both COPD and sleep apnea-hypopnea than with either of those alone.

How Are Co-existing COPD and Sleep-Related Breathing Disorders Best Managed?

The treatment for patients with overlap syndrome should generally start with continuous positive airway pressure (CPAP), as guided by findings from full polysomnography, using current recommendations outlined for patients with OSA. Supplementation with O2 may be necessary in addition to CPAP for those overlap patients with more severe COPD and cor pulmonale, and the continued need for LTOT can be re-evaluated later. Optimizing other co-morbid conditions such as left-ventricular dysfunction and other cardiovascular complications should also be addressed in these patients.

Patients with obesity hypoventilation syndrome may develop hypoventilation insidiously as weight gain advances and other organ system dysfunction occurs. As daytime gas exchange abnormalities develop, and especially with the development of cor pulmonale, associated sleep deterioration is often observed. Polysomnography is often indicated to rule out an OSA component, but a trial of NPPV can also be initiated at this time; NPPV is efficacious in patients with obesity hypoventilation syndrome. NPPV may be especially useful with patients who require frequent hospitalization and who do not respond to or are intolerant of CPAP. A recent consensus conference suggested that polysomnography should be performed to rule out OSA before considering NPPV for a patient with nocturnal hypoventilation due to causes other than COPD or neuromuscular disease. A CPAP trial is recommended if OSA is predominant, unless CPAP has previously failed or it is unlikely that the hypoventilation will respond to CPAP.

Nicholas Hill discusses NPPV treatment of COPD patients in more detail in another report in this Journal Conference, so the present report will concentrate primarily on the issues that pertain to sleep and nocturnal gas exchange. Since little has been published on sleep quality with negative-pressure ventilatory support or mechanical ventilation through a tracheostomy, my remarks will be confined to NPPV treatment alone. The results of studies with patients suffering severe COPD and hypercapnia have been discrepant with respect to both gas exchange and sleep quality, which may relate to both patient selection issues and methodology, particularly choice of ventilator settings. Given that the issues of optimal ventilator mode, support level, and interface choice remain unresolved, the true effect of NPPV on sleep architecture is also controversial. Most ventilator adjustments in these studies were guided by forcing the patient to maximum tolerance levels of pressure support with mean inspiratory positive assist pressure of 10–22 cm H₂O. Only in the study with the highest mean inspiratory positive assist pressure (≥18 cm H₂O) did patients with severe COPD show significant but small increases in sleep efficiency and total sleep time. Another unique aspect in this study was the increased nocturnal PaCO₂ when NOT was given alone, compared to with NPPV, and there was a correlation between rising nocturnal versus diurnal PaCO₂, (Fig. 6). These researchers also enrolled patients with the highest apnea-hypopnea threshold, 10 events per hour, as opposed to a cutoff of 5 events per hour in all the other unsuccessful studies noted above. This again supports the concept that those severe-COPD patients who show worsening hypercapnia with LTOT are probably having worsening hypoventilation with LTOT at night and may be the best candidates for a trial of NPPV (Fig. 7). Sleep architecture and the number of arousals is usually unchanged before and after NPPV, but REM sleep percentage remains reduced, compared to normal older adults (Table 1). This can relate to the fact that patients may be aroused due to discoordination of the upper airway/glottic opening with the timing of inhalation, and special attention should also be given to mouth leak and poor mask fit. Optimizing coordination between patient and ventilator may be key to reducing the more-frequent sleep-stage changes frequently seen with NPPV.

How Is the Management of Sleep-Related Breathing Disorders in COPD Patients Complicated by Process and Reimbursement Issues?

The major process barriers encountered by the clinician during the management of sleep-related breathing disorders in COPD patients can best be discussed first in terms of deciding about specific treatment goals or targets. The implementation of treatment must also be carefully thought out to avoid additional difficulties for delivery of optimal care. The therapies under consideration here involve oxygen therapy and NPPV. Although the comments that follow regarding reimbursement will soon be outdated because of the frequent reappraisals, the necessity for the clinician to keep in touch with current coverage criteria can easily be appreciated.

Oxygen

The questions when determining the goals of NOT are: What is the threshold saturation level for treatment, and
what is the necessary vigor of maintenance above an oxygen desaturation limit? Although sleep quality is another consideration and may be subjectively improved with oxygen therapy, there is little objective evidence that sleep quality should be used as a treatment goal.

How to determine the threshold saturation and vigor of saturation maintenance may be influenced by the presence and degree of pulmonary hypertension, especially in patients with more severe COPD and NOD. Where to make the decisions is usually a practical concern, but oxygen therapy is typically determined during an office visit when continuous LTOT is needed. Home overnight oximetry before and after selection of nocturnal oxygen flow rates should usually be done for optimal management. Given the paucity of data to enlighten practitioners in either regard, however, it is understandable that both targets are not clear-cut. Each of these decisions is probably best individualized by the treating caregiver, but some more specific guidelines are offered below.

The current Centers for Medicare and Medicaid Services coverage criteria are relatively liberal and allow ready access according to most of the evidence reviewed above. The criteria most pertinent for this discussion deal with NOT, which is permitted when the threshold is met for 24-hour LTOT, but there are also specific requirements for patients who have nocturnal hypoxemia alone that are less stringent in the presence of other medical problems such as cor pulmonale. There is some concern about the present language, and one of the revisions proposed in the draft policy that was released for comment in July 2001 was to change the coverage criterion for oxygen when it is based solely on a nocturnal oximetry study, as explained below.

**Current and Draft Oxygen Coverage Criteria.** Home oxygen therapy is currently covered only if all of the following conditions are met:

- Group I criteria include either (1) awake $P_{aO_2} \leq 55$ mm Hg or $S_{aO_2} \leq 88\%$ or (2) asleep $S_{aO_2} \leq 89\%$ for at least 5 continuous minutes, with a nadir of $\leq 85\%$.
- Group II criteria include the presence of criterion A or B (below) plus criterion 1, 2, or 3 (below).

A: Awake (at-rest or during exercise) $P_{aO_2}$ of 56–59 mm Hg or $S_{aO_2} \leq 89\%$

B: $S_{aO_2}$ decrease of $> 5\%$ for at least 5 continuous minutes, with a nadir of $\leq 85\%$ during sleep.
1. Dependent edema due to congestive heart failure, or
2. Pulmonary hypertension or cor pulmonale, determined by measurement of pulmonary artery pressure, gated blood pool scan, echocardiogram, or “P pulmonale” on electrocardiogram, or
3. Erythrocythemia with hematocrit > 56%

The draft policy initially proposed qualification criteria similar to the above but included a clause to consider mandating recertification for LTOT. Under scrutiny are patients who were given LTOT during recovery from a COPD exacerbation and who may not need continued LTOT yet keep it for “convenience” and subjective benefit, which further increases the high costs of LTOT delivery and should probably be curtailed. Although recertification is proposed in the draft policy, it is unlikely this will be acceptable, given that oximetry reimbursement is limited at best and would pose an additional cost and inconvenience. Another alternative would be to consider attaching more specific payment methods to the various oxygen delivery systems (liquid oxygen, compressed gas, and oxygen concentrator).

Noninvasive Positive-Pressure Ventilation

The treatment goals of NPPV are primarily determined by what must be done to address individual patient complaints or requests for symptom relief. Since evidence does exist for improved sleep quality, especially for those with OSA, but also for those with COPD alone, this goal may be reasonable and achievable in patients with severe sleep disruption. How this is best accomplished with NPPV is more problematic, as questions remain regarding whether ventilator settings that achieve maximum $V_e$ also optimize sleep quality. Where to initiate and assess optimal NPPV settings is easily determined when more obvious overlap and obesity hypoventilation clinical features are present. There is a clear need to achieve upper-airway patency and increased inspiratory flow for hypoventilation in this subset of COPD patients. A recent intriguing finding is that patients who demonstrate improved sleep quality on initial use of CPAP have much better long-term CPAP-therapy adherence, so clinicians should strive to create an optimal initial CPAP experience. The use of hypnotic medications to facilitate the adjustment to NPPV has not been formally studied but should be.

With respect to reimbursement, certain patients must undergo polysomnography to qualify for reimbursement. Presently there are only 3 categories in which to qualify patients with COPD and sleep-related breathing disorders for NPPV, and they fall under the primary diagnoses of either severe COPD, central sleep apnea, or intolerance of CPAP for OSA. The major reimbursement issue that complicates NPPV treatment pertains to the prescription of a backup rate, which is very difficult in coverage category II and III and not allowed at all in category IV (see below). The consensus guideline recommendations noted above and those in the Summary (below) leave much of this decision-making to the discretion of the treating physician.

The current (as of December 1999) NPPV coverage categories (I–IV) and criteria are:

| I | Restrictive lung disease. This category is not applicable to COPD. |
| II | Severe COPD: |
| A1 | $F_aCO_2 \geq 52$ mm Hg while the patient is awake and breathing his or her usual fraction of inspired oxygen ($F_{IO_2}$), and |
| A2 | $S_{PO_2} < 88\%$ for at least 5 continuous minutes while the patient is asleep and receiving oxygen at 2 L/min or his or her usual $F_{IO_2}$, whichever is higher, and |
| A3 | Prior to initiating therapy, OSA and CPAP have been considered and ruled out. |
| B1 | A K0532 device (without a backup rate) will be covered for the first 3 months, but the patient |

### Table 1. Summary of Sleep Data from Chronic Obstructive Pulmonary Disease Patients Who Received Noninvasive Positive-Pressure Ventilation

<table>
<thead>
<tr>
<th>Authors</th>
<th>n</th>
<th>Disease</th>
<th>TST</th>
<th>Efficiency</th>
<th>% REM</th>
<th>Arousals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strumpf et al²⁹</td>
<td>7</td>
<td>COPD</td>
<td>NC</td>
<td>NC</td>
<td>NC</td>
<td>U</td>
</tr>
<tr>
<td>Meecham-Jones et al³⁰</td>
<td>18</td>
<td>COPD</td>
<td>↑↑</td>
<td>↑↑</td>
<td>↑↑</td>
<td>U</td>
</tr>
<tr>
<td>Gay et al³¹</td>
<td>4</td>
<td>COPD</td>
<td>NC</td>
<td>NC</td>
<td>↓↓</td>
<td>U</td>
</tr>
<tr>
<td>Lin³²</td>
<td>12</td>
<td>COPD</td>
<td>U</td>
<td>↓↓</td>
<td>NC</td>
<td>U</td>
</tr>
<tr>
<td>Krachman et al³³</td>
<td>6</td>
<td>COPD</td>
<td>↑↑</td>
<td>↑↑</td>
<td>NC</td>
<td>NC</td>
</tr>
</tbody>
</table>

TST = total sleep time  
% REM = percent of time in rapid-eye-movement (REM) sleep  
↑↑ = significantly improved  
NC = no change  
↓↓ = significantly worse  
U = data unavailable
must be reassessed (61–90 days after the initiation of therapy) for adequate therapy-adherence, to ensure continued coverage.

B2: A K0533 device (with a backup rate) will not be covered until after the first 2 months and only when the patient has been compliant with a K0532 device and has not improved.

III Central sleep apnea (ie, apnea not due to airway obstruction):
A: The diagnosis of central sleep apnea, based on complete facility-based, attended polysomnography, and
B: OSA is excluded as the predominant cause of sleep-associated hypoventilation, and
C: The ruling out of CPAP as effective therapy if OSA is a component of the sleep-associated hypoventilation, and
D: Oxygen saturation < 88% for at least 5 continuous minutes, measured while the patient is breathing his or her usual FIO\textsubscript{2}, and
E: Substantial improvement of the sleep-associated hypoventilation with the use of a K0532 or K0533 device on the settings that will be prescribed for initial use at home, measured while the patient is breathing his or her usual FIO\textsubscript{2}.

IV Obstructive sleep apnea:
A: A complete facility-based, attended polysomnography has established the diagnosis of OSA and
B: A single-level (E0601) CPAP device has been tried and proven ineffective.

A looming concern relates to the category of payment that the K0533 backup rate device falls under, which is one requiring frequent servicing with indefinite coverage, as opposed to the “capped rental” with fixed payment duration, like CPAP. It is very likely there will be a policy change, to switch the K0533 to the “capped rental” coverage category and thereby reduce reimbursement and patient services to an indeterminate but concerning level.

What Are the Summary Indications for Supplemental Oxygen and NPPV During Sleep in COPD Patients?

Summarizing the information above, it is assumed that the normal mechanisms that control breathing during sleep are intact for COPD patients but the responses are blunted, generally leading to hypoventilation and gas exchange abnormalities, particularly in REM sleep. This is most profound for severe-COPD patients, especially those showing worsening hypercapnia with LTOT. Patients who suffer worsening hypventilation with LTOT at night would probably be the best to consider for a trial of NPPV, presuming that concerns about OSA have been appropriately addressed. Sleep architecture and the number of arousals, however, may not be greatly improved by NPPV, compared to normal older adults. Nevertheless, I believe the following recommendations are reasonable regarding NPPV for patients with severe COPD.

Oxygen

The effects on survival and pulmonary hemodynamics clearly support oxygen therapy for COPD patients. The most contentious issue regards the need for oxygen in COPD patients with NOD (with no universally accepted level) in the absence of current indications for 24-hour oxygen therapy. Although current ATS guidelines recommend treatment only for more extreme desaturation (nocturnal $S_{\text{aO}_2} \leq 90% > 30%$ of the time), the Centers for Medicare and Medicaid Services coverage criteria are much more liberal ($S_{\text{aO}_2} < 89%$ for 5 continuous minutes). There is nevertheless persuasive evidence of worse survival in patients who have $S_{\text{aO}_2} \leq 90%$ for 5 min and nadir saturation $\leq 85%$. Both the ATS and ERS updated guidelines and the revised Centers for Medicare and Medicaid Services coverage criteria for oxygen therapy are pending but, based on the available data, as stated above, it seems prudent to recommend that:

1. Continuous oxygen therapy is justified in patients with awake $P_{\text{aCO}_2} \leq 55$ mm Hg or $S_{\text{aO}_2} \leq 89%$. Oxygen flow should be controlled to maintain a target $S_{\text{aO}_2}$ of $\geq 90%$, with increased oxygen flow as needed, and with special efforts to assess this via additional monitoring during the hours of sleep.

2. With patients who do not meet criteria 1, NOT should be considered for patients with $S_{\text{aO}_2} \leq 90%$ for 20 min, with a targeted attempt to maintain $S_{\text{aO}_2} \approx 90%$.

3. Although evidence is limited, oxygen therapy may be considered for less total time (5 min) with $S_{\text{aO}_2} \leq 90%$, at the discretion of the treating clinician, in the presence of other cardiopulmonary or cerebrovascular disorders such as pulmonary hypertension, arrhythmia, left ventricular dysfunction, angina, or stroke.

Noninvasive Positive-Pressure Ventilation

These recommendations regarding NPPV for COPD patients are confined to effects on improvement in sleep quality and nocturnal gas exchange. Based on guidelines from the NPPV consensus conference and other evidence described above, it seems prudent to recommend that:

1. Patients with COPD and awake chronic $P_{\text{aCO}_2} \geq 55$ mm Hg, and who are receiving otherwise optimal therapy, should be considered for nocturnal NPPV without a backup rate; therapy may be guided by empirical ventilator settings, overnight oximetry, and awake blood gas values.

2. Patients with $P_{\text{aCO}_2}$ of 50–55 mm Hg who have obesity or worsening hypercapnia on LTOT or NOT alone...
should be considered for complete polysomnography. In the presence of OSA, CPAP could be tried and should be proven ineffective before introducing NPPV, unless the patient’s severity of disease is unlikely to respond to CPAP.

3. In all cases, aggressive continued monitoring of blood gas values or nocturnal $S_{\text{PO}_2}$ and optimization of alternative therapies should take place as indicated. Further observation in the laboratory with full polysomnography should be considered for patients who are not improving, with attempts to observe REM sleep state to best decide on the need for a backup rate or additional oxygen.

Studies clearly need to be continued to further explain the true effect of NPPV on sleep quality and control of breathing, both on an immediate and sustained basis. Until the mechanisms to explain the benefit of NPPV for COPD and other sleep-related breathing disorders are better known, the indications, ideal ventilator settings, and expected response will remain unclear.

REFERENCES


36. Report of the Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale com-


Discussion

Enright: Are you treating the physician, or are you treating the patient? Improving physiologic variables doesn’t always result in improved quality of life for the patient. I don’t understand which goals of the therapy help the patient. Are you trying to make them live longer? I didn’t see any data that suggested that.

Gay: Dr Nick Hill will talk about mortality issues in his presentation to this Journal Conference.1

Enright: Both. What is the therapeutic goal? Are you trying to increase the duration of life? Increase the quality of life? Or are you just trying to bring physiologic measurements into the normal range of a healthy person without COPD?

Gay: I think for supplemental oxygen the arguments are a lot more difficult and it’s not easy to be precise about the targets, but for NPPV I emphasize the fact that COPD and OSA are often co-existing disorders. I think these people have OSA problems such as sleepiness, and they are better when you treat that, as opposed to what I think you’re saying, which is that in the patient with pure COPD you’re maybe just treating the gas-exchange abnormality without substantial symptomatic benefit, and I actually agree with you.

But for the patients who are symptomatic with sleep disruption and you put them in the laboratory and they get better, everyone would agree that that’s of value to the patient. The data from randomized, controlled trials (both short-term in Gerry Criner’s group,1 and in the other long-term 3 studies2–4) showed some benefit with sleep, certainly in the largest group of patients in the Meecham-Jones study, who had more than just COPD. They had a disorder of ventilation during sleep, and they became more hypercapnic with supplemental oxygen. Perhaps I can accept some of your argument focusing on pulmonary hypertension and on improvement in daytime gas exchange alone as somewhat ignoring patient symptom-relief. In my study the placebo group was the most compliant.3 The other patients would send the box back. So I think it’s important to recognize that it’s the combined disorders that are most likely to benefit from NPPV. Recognition of an additional hypoventilation component in those patients will, I think, dramatically improve this subset of COPD patients.

REFERENCES

Enright: So it’s the daytime sleepiness I should be aware of with any patient, regardless of whether they
have COPD? Is that what I’m looking for that would tell me to look at their nocturnal oxygen saturation or even do a full polysomnogram, because that’s what I’m trying to fix?

Gay: That with other features that suggest worsening hypoventilation. I’m amazed at how infrequently even some of my own colleagues take a sleep history, when they’re so focused on COPD. Daytime sleepiness is not a very good marker. These are patients who are miserable. They’re just trying to get through the day, and they just think daytime sleepiness and fatigue is what they’re going to have. So thinking, “Oh, I’ll find a symptom, and now I’ll find a reason to treat it with NPPV,” is naive. I don’t think that’s going to get all the answers and pick out those people who will benefit.

MacIntyre: What about patients in a pulmonary rehabilitation group who come with baseline $P_{O_2}$ in the mid-60s or 70s [mm Hg], but who desaturate quite a bit during exercise on stationary bike or walking? We put them on oxygen during their exercise periods. Is there any correlation between exercise desaturation and sleep desaturation?

Gay: There is some, but it’s a weak correlation. It’s difficult to predict nocturnal desaturation from other studies. I think the take-home lesson is that just about nothing during the daytime, except significant hypoxemia that qualifies for continuous oxygen, tells you, “Aha, this patient should get nocturnal oxygen.”

Giordano:* Regarding your description of the “capped rental,” you were accurate as far as you went, but there is another piece to it, which is that after 15 months of rental the home medical equipment supplier will be paid the equivalent of 1 month’s rent every 6 months to maintain the equipment. So there is a bit of a tail on the payments, and I just want to make sure we describe the entire process.

Fahy: I discuss sleep with my patients during the initial assessment and they often say, “I sleep as well as I should be sleeping, I guess.” But then I get them into an education class and, though I’m pretty loud when I lecture, they’re sleeping through my lecture. I call the referring doctor and say maybe that patient should get a sleep study, and we’ve identified quite few patients who require CPAP or nocturnal ventilation of some sort.

Gay: These patients have so many obstacles in front of them; trying to convince them that improving their sleep should be a priority can be difficult and often doesn’t come up.

Hill: One of the things that struck me about sleep-disordered breathing in patients with severe COPD is the remarkable individual variability. In the non-invasive ventilation study we did with David Strumpf, we excluded patients who had more than 5 apneas or hypopneas per hour, and those people maintained essentially normal oxygen saturation all night without oxygen supplementation. Those patients had severe airway obstruction with $FEV_1$ averaging about 500 mL, but patients with much less obstruction may have far worse nocturnal oxygenation and frequent desaturations. Physiologically, what do you think explains that kind of variability? Is it central drive? Is it that the patients who have less desaturation have less REM-sleep? What’s going on there?

REFERENCE

Gay: I’ve got to be honest and say I really don’t know. Obviously, there are multiple mechanisms, and how they interact ultimately determines gas exchange. It’s pretty clear that those single items—the severity of $FEV_1$ abnormality and the apnea-hypopnea index in the overlap patients—do not predict the combination result that you see at night in these patients. I think that’s why a lot of these where the oximetry studies that are simple and available really should be used more frequently in these patients. You can’t predict very well from the history alone.

Wedzicha: Something that confuses me is increasing oxygen flow at night. Some physicians advocate increasing the oxygen flow rate at night in patients who desaturate but I would argue that these are the patients with whom you do not want to increase the oxygen flow. My practice is to keep oxygen at the same level, 2 L/min, overnight. What do you do in practice, and what do you believe we should all do?

Gay: That’s an excellent question. I really appreciate your bringing that up, because the focus is on gas exchange there. In essence, if I turn the oxygen up to improve the oxygenation, I may overlook the fact that the carbon dioxide has been chasing that through the night and blood gas values are worse during the day. The focus should be not only on maintaining oxygenation, but also asking whether hypercapnia is getting worse. I think those are the patients you want to consider for NPPV. That’s overlooked when you’re wearing your “oxygenation hat.” Sure, I can make oxygenation look better, but that may not be better for the patient.

* Sam P Giordano MBA RRT FAARC, Executive Director, American Association for Respiratory Care, Dallas, Texas.
OXYGEN AND AIR TRAVEL
A CLINICIAN'S GUIDE

Background

On July 12th, 2005 the Federal Aviation Administration (FAA) published Special Federal Aviation Regulation (SFAR) 106 in the Federal Register (vol. 70, no. 132). The new regulation provides the airlines, passengers and device manufacturers with the rules for use of portable oxygen concentrator systems (POCs) onboard aircraft. The rule became effective August 11th, 2005 and is expected to have a major impact on travel for long term oxygen therapy (LTOT) users. Conservative estimates suggest this new ruling will add more than 50,000 new air travelers annually. As more LTOT travelers hit the skies, more questions will develop regarding the effects of altitude on persons with lung disease and those requiring supplemental oxygen at ground level.

This document was developed to provide clinicians with basic information regarding the potential physiologic effects of altitude on persons with lung disease.

Clinical & Technical Considerations

Oxygen inside the cabin during flight. The partial pressure of oxygen in the ambient air is a product of the barometric pressure and the atmospheric fraction of oxygen (0.209) as represented in the equation: \[ \text{Barometric Pressure} \times 0.209 = \text{Atmospheric PO}_2 \]. At sea level this is represented as: \[ 760 \times 0.209 = 159 \text{ mmHg} \]. Most commercial aircraft cabins are pressurized to an altitude of approximately 5,000 - 8,000 feet. At 8,000 feet, the partial pressure of \( \text{O}_2 \) in the cabin is 564 mmHg \( \times 0.209 = 118 \text{ mmHg} \). Gas density at 8,000 feet is almost 30% lower than sea level. With less driving pressure available, the net clinical effect at the interface of the alveoli and pulmonary capillaries is that similar to breathing approximately 15.1% \( \text{O}_2 \) at sea level.\(^1\)

Predicting blood oxygen levels at altitude. There is no single, evidenced-based, standardized method of predicting blood oxygen levels at altitude, especially for patients with chronic lung disease. As a general rule of thumb, it is estimated that inspired \( \text{PO}_2 \) declines approximately 5 mmHg per 1,000 feet ascended. There is no such general rule governing potential changes to \( \text{SpO}_2 \) at altitude. A number of predictive, regression equations have been derived from various clinical studies yet may not prove accurate or effective as part of an individual patient evaluation for predicting blood oxygen levels during flight.\(^2,3,4\) A hypobaric challenge (i.e., having a patient breath 15.1% gas) while at sea level may prove to serve as an effective predictor of blood oxygen levels during flight but may not be practical for many outpatient offices to perform.

LTOT patients and air travel. For patients prescribed LTOT for use at home, there is no evidenced-based or expert consensus guideline for prescribing oxygen for use in flight. A patient’s baseline hypoxemia, oxygen prescription at ground level, respiratory reserve, level of hemoglobin and general clinical condition prior to flight are all key variables influencing in-flight oxygen use. In his paper titled “Oxygen and Air Travel” published in Respiratory Care, Stoller notes that despite the protean effects of altitude exposure, relatively brief exposure to altitude (i.e., <12 hours) encountered during commercial flight seems to be well tolerated, even among patients with chronic lung disease.\(^5\) It is generally accepted that patients with a ground level \( \text{PaO}_2 \) of >80 mmHg will experience no difficulty during flight and patients with a \( \text{PaO}_2 \) of <60 mmHg at ground level will need oxygen at altitude. Patients predicted to have an in-flight \( \text{PaO}_2 \) ≤50 mmHg are clearly candidates for using supplemental oxygen during flight.\(^5\) Depending on their clinical condition at the time of flight and their baseline (ground level) supplemental oxygen corrected \( \text{PaO}_2 \), some LTOT users may need to increase their oxygen dose (i.e., flow setting or setting on the oxygen conserving device) to ensure adequate oxygenation during flight. The decision to prescribe oxygen during flight or to alter a patient’s ground level oxygen prescription for use during flight is one best made by the patient’s attending physician. Therefore, it is recommended that all patients with chronic lung disease be seen and evaluated by their physician prior to scheduling any air travel.\(^5\)

---

\(^5\) Stoller JK. “Oxygen and Air Travel”. Respir Care 2000 Feb;45(2):214-221
SUGGESTED READING AND HELPFUL INTERNET LINKS

Peer Reviewed Manuscripts

1. Stoller JK. “Oxygen and Air Travel”. Resp Care 2000 Feb;45(2):214-221

Links for Additional Information on Oxygen and Air Travel

www.inogen.net
www.thoracic.org/chapters/california/publications.asp
www.aarc.org
OXYGEN AND AIR TRAVEL
A CLINICIAN'S GUIDE

Background

On July 12th, 2005 the Federal Aviation Administration (FAA) published Special Federal Aviation Regulation (SFAR) 106 in the Federal Register (vol. 70, no. 132). The new regulation provides the airlines, passengers and device manufacturers with the rules for use of portable oxygen concentrator systems (POCs) onboard aircraft. The rule became effective August 11th, 2005 and is expected to have a major impact on travel for long term oxygen therapy (LTOT) users. Conservative estimates will add more than 50,000 new air travelers annually. As more LTOT travelers hit the skies, more questions will develop regarding the effects of altitude on persons with lung disease and those requiring supplemental oxygen at ground level.

This document was developed to provide clinicians with basic information regarding the potential physiologic effects of altitude on persons with lung disease.

Clinical & Technical Considerations

Oxygen inside the cabin during flight. The partial pressure of oxygen in the ambient air is a product of the barometric pressure and the atmospheric fraction of oxygen (0.209) as represented in the equation: Barometric Pressure x 0.209 = Atmospheric PO2. At sea level this is represented as: 760 x 0.209 = 159 mmHg. Most commercial aircraft cabins are pressurized to an altitude of approximately 5,000 - 8,000 feet. At 8,000 feet, the partial pressure of O2 in the cabin is 564 mmHg x 0.209 = 118 mmHg. Gas density at 8,000 feet is almost 30% lower than sea level. With less driving pressure available, the net clinical effect at the interface of the alveoli and pulmonary capillaries is that similar to breathing approximately 15.1% O2 at sea level.

Predicting blood oxygen levels at altitude. There is no single, evidenced-based, standardized method of predicting blood oxygen levels at altitude, especially for patients with chronic lung disease. As a general rule of thumb, it is estimated that inspired PO2 declines approximately 5 mmHg per 1,000 feet ascended. There is no such general rule governing potential changes to SpO2 at altitude. A number of predictive, regression equations have been derived from various clinical studies yet may not prove accurate or effective as part of an individual patient evaluation for predicting blood oxygen levels during flight. A hypobaric challenge (i.e., having a patient breath 15.1% gas) while at sea level may prove to serve as an effective predictor of blood oxygen levels during flight but may not be practical for many outpatient offices to perform.

LTOT patients and air travel. For patients prescribed LTOT for use at home, there is no evidenced-based or expert consensus guideline for prescribing oxygen for use in flight. A patient’s baseline hypoxemia, oxygen prescription at ground level, respiratory reserve, level of hemoglobin and general clinical condition prior to flight are all key variables influencing in-flight oxygen use. In his paper titled “Oxygen and Air Travel” published in Respiratory Care, Stoller notes that despite the protean effects of altitude exposure, relatively brief exposure to altitude (i.e., <12 hours) encountered during commercial flight seems to be well tolerated, even among patients with chronic lung disease. It is generally accepted that patients with a ground level PaO2 of >80 mmHg will experience no difficulty during flight and patients with a PaO2 of <60 mmHg at ground level will need oxygen at altitude. Patients predicted to have an in-flight PaO2 ≤50 mmHg are clearly candidates for using supplemental oxygen during flight. Depending on their clinical condition at the time of flight and their baseline (ground level) supplemental oxygen corrected PaO2, some LTOT users may need to increase their oxygen dose (i.e., flow setting or setting on the oxygen conserving device) to ensure adequate oxigenation during flight. The decision to prescribe oxygen during flight or to alter a patient’s ground level oxygen prescription for use during flight is one best made by the patient’s attending physician. Therefore, it is recommended that all patients with chronic lung disease be seen and evaluated by their physician prior to scheduling any air travel.

---

2 Mortazavi, A; Eisenberg, MJ; Langlben, D, et al. Altitude-related hypoxia: risk assessment and management for passengers on commercial aircraft. Aviat Space Environ Med 2003; 74:922
5 Stoller JK. “Oxygen and Air Travel”. Resp Care 2000 Feb;45(2):214-221
OXYGEN AND AIR TRAVEL
A CLINICIAN'S GUIDE

SUGGESTED READING AND HELPFUL INTERNET LINKS

Peer Reviewed Manuscripts

1. Stoller JK. “Oxygen and Air Travel”. Resp Care 2000 Feb;45(2):214-221

Links for Additional Information on Oxygen and Air Travel

www.inogen.net
www.thoracic.org/chapters/california/publications.asp
www.aarc.org
Oxygen Conserving Technology
Peer Review Bibliography

Nocturnal Use of Oxygen Conserving Devices

The following are published clinical studies that demonstrate the effective use of oxygen conserving devices in a variety of clinical and patient conditions, including use during sleep.

   i) Summary: the purpose of this study was to determine if a single titration of oxygen using a POC during ambulation/exercise would provide an appropriate setting for nocturnal use. The results suggested that an oxygen setting selection based on daytime ADL/ambulation appears to produce effective nocturnal oxygen therapy as evidenced by a mean sleeping SpO₂ of 92% and no clinically significant desaturation in any study participant.

2. Chatburn, R, Lewarski J, McCoy R. “Nocturnal oxygenation using a pulsed dose oxygen conserving device compared to continuous flow oxygen.” *Respir Care* March 2006;51(3): 252-256
   i) Summary: the study compared nocturnal oxygenation with continuous flow versus the Inogen One among a group of established LTOT users with chronic lung disease. The results support demonstrates that when appropriately titrated, the Inogen One is essentially clinically equivalent to continuous flow oxygen. The study also suggests that daytime pulse dose titrations may be effective in determining nocturnal oxygenation.

   i) Summary: This is a very comprehensive review of the clinical issues and related science regarding COPD and sleep. The paper reviews in detail the science and issues regarding oxygen use with sleep.

   i) Summary: editorial review of current issues associated with sleep and lung disease, including COPD and oxygen. Discusses briefly the use of oxygen conservers in sleep based on the work of Cuvelier, et al (see below).

   i) Summary: compared efficacy of continuous flow versus pulse dosed oxygen in sleeping, hypoxemic patients measured through polysomnography. Concluded that the use of a pulse dosing oxygen delivery device did not induce any significant alteration physiologic parameters, as compared to continuous flow, in the majority of moderate to severe COPD patients requiring supplemental oxygen.

   i) Summary: large (n=100), unblinded crossover study comparing continuous flow oxygen versus pulse dosed oxygen delivery in hospitalized patients. Concluded that both oxygen systems produce similar SpO₂ levels in hypoxic patients over the course of day and night.

   i) Summary: compared continuous flow to demand pulse dosed oxygen during all patient activities, including sleep. Concluded that demand oxygen systems produced arterial oxygenation equivalent to continuous flow during all activities.
Efficacy of Pulse Dosing Concentrator Produced Oxygen

The following published studies demonstrate the clinical efficacy of pulse dosed oxygen produced from a concentrator as studied in a variety of applications

   i) Summary: the study concluded that the Inogen One was as clinically effective as continuous flow oxygen at maintaining target SpO2 levels in high flow (4-5 lpm) oxygen users during intense exercise.

2. Stegmaier, J. “Mobility, remote activity & power supply utilization among oxygen dependent patients using a lightweight portable oxygen concentrator system.” Abstract. Respir Care November 2005;50(11):1507
   i) Summary: the study suggests that the power supply strategy of the Inogen One is very effective in meeting the ambulatory and mobility needs of highly active oxygen users. The 2-3 hour battery duration of the Inogen One does not inhibit remote activity, as patients were consistently able to access external power (AC or DC) during the course of their activities.

   i) Summary: study concluded that there is no clinical or statistical difference in physiologic response and SpO2 in exercising patients receiving continuous flow USP gas vs. pulsed dose gas produced in an oxygen concentrator.

   i) Summary: study concluded that oxygen delivered via pulse dose from cylinders filled by concentrators is clinically equivalent to continuous flow oxygen delivered to exercising patients.

Nocturnal Oxygenation & Desaturation in Continuous Flow Oxygen Therapy

   i) Summary: Detailed, evidenced supported review of management of COPD. Establishes the definition of clinically significant nocturnal desaturation as an SpO2 < 90% for >30% of the sleep time. Also recognizes the incident of desaturation in sleeping LTOT users and suggests increasing O2 setting by 1 L/Min to compensate for reduced minute ventilation.

   i) Summary: large study (n = 82) of existing LTOT users well-managed with SpO2 >90% on their usual O2 prescription during the day. Studied concluded that nearly 50% of the patients experienced clinically significant (ATS definition) nocturnal desaturations on their usual oxygen prescription.

   i) Summary: Studied examined early morning ABGs and nocturnal SpO2 in 39 patients on LTOT. Patients spent an average of 28% of their sleep time with an SpO2 < 90%.
Nocturnal Oxygenation & Desaturation in Continuous Flow Oxygen Therapy

   i) Summary: Study examined 24-hour oximetry data in 34 existing LTOT users and concluded that the basic prescription for LTOT was inadequate and failed to maintain appropriate SpO2 levels for 85% of the patients. This was most evident with strenuous activity and during sleep.

   i) Summary: Studied group included 101 patients and used overnight oximetry to evaluate nocturnal oxygenation. Researchers concluded that 33% of the COPD patients experienced desaturation and would benefit from an increased O2 flow during sleep.